Annovis Bio Inc. (ANVS) Prices 2M Share IPO at $6/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Annovis Bio Announces Pricing of Initial Public Offering
January 28, 2020 11:31 PM ESTBERWYN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases today announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a price to the public of $6.00 per share, for gross proceeds of $12,000,000 before deducting underwriting discounts, commissions and offering expenses. In addition, Annovis Bio, Inc. has granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of its common stock to cover over-allotments at the initial public offering price less underwriting discount. All of the shares... More
